News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

News|Videos|October 10, 2023

EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA

Author(s)Benjamin M. Brucker, MD, Eman A. Elkadry, MD, Jenna K. Horton, NP

Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.

Sponsored by AbbVie US Medical Affairs

Episodes in this series

EP. 1 In-Clinic Educational Resource on the OAB Treatment Pathway

EP. 1 In-Clinic Educational Resource on the OAB Treatment Pathway

Experts on OAB

EP. 2 EP. 1: An Introduction of the Speakers

Expert on OAB

EP. 3 EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations

Expert on OAB

EP. 4 Ep. 3: The Typical Patient with OAB and Common Signs and Symptoms

Expert on OAB

EP. 5 EP. 4: The Role of Urodynamic Testing in OAB Evaluation

Experts on OAB

EP. 6 EP. 5: OAB Treatment: Available Strategies and Rationale for Use

Expert on OAB

EP. 7 EP. 6: Factors Informing Selection of Pharmacologic Treatment for OAB

Expert on OAB

EP. 8 Ep. 7: Defining Pharmacologic Treatment Failure in Patients with OAB and Subsequent Treatment Strategies

Expert on OAB

EP. 9 EP. 8: Patient-Clinician Conversations Regarding Initial Pharmacologic Treatment for OAB

Experts on OAB

EP. 10 EP. 9: Treatment Goals and Educational Resources for Patients on Initial Pharmacologic Therapy for OAB

Expert on OAB

EP. 11 EP. 10: Third-Line OAB Therapies and Patient-Centered Decision-Making

Expert on OAB

EP. 12 EP. 11: Setting Treatment Expectations for Patients with OAB Receiving Third-Line Therapies

Expert on OAB

EP. 13 EP. 12: OAB Patient Monitoring and Followup Considerations in the Third-Line Treatment Setting

Experts on OAB

EP. 14 EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA

Expert on OAB

EP. 15 EP. 14: SNM and PTNS for OAB: Device Management and Followup

Expert on OAB

EP. 16 EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB

This content is intended for US/PR Healthcare Professionals.

The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content

5 women's health FDA headlines you missed in Q2 2026| Image credit: Contemporary OB/GYN

5 women's health FDA headlines you missed in Q2 2026

ByJoshua Fitch, Senior Editor

June 29th 2026

FDA approves tebipenem pivoxil as first oral carbapenem antibiotic for complicated urinary tract infections | Image credit: Contemporary OB/GYN

FDA approves tebipenem pivoxil as first oral carbapenem antibiotic for complicated urinary tract infections

ByJoshua Fitch, Senior Editor ,Benjamin P. Saylor

June 17th 2026

FDA approves cefepime and zidebactam intravenous antibiotic to treat adults with cUTI

FDA approves cefepime and zidebactam intravenous antibiotic to treat adults with cUTI

ByJoshua Fitch, Senior Editor

June 1st 2026

Nitrofurantoin outperformed fosfomycin for uncomplicated UTIs in randomized trial

Nitrofurantoin outperformed fosfomycin for uncomplicated UTIs in randomized trial

ByJoshua Fitch, Senior Editor

May 29th 2026

Aleece Fosnight, MSPAS, PA-C, on why new-onset incontinence in women warrants thyroid evaluation

ByAleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES

March 25th 2026

Latest CME

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Trending on Contemporary OB/GYN

Updated: CMS proposed G-codes for obstetric billing draw concern from ACOG amid coding transition

FDA grants 510(k) clearance to Roche's cobas BV/CV assay

Natural Cycles receives FDA clearance for AI-powered fertility algorithm

HIV screening, PrEP counseling get stronger ACOG recommendation

Late preterm hypoglycemia not tied to neurodevelopment at age 6